- Home
- EDIT
EDIT
Editas Medicine Inc.
as of 03-11-2026 4:00pm EST
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 206.0M | IPO Year: | 2016 |
| Target Price: | $4.92 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | 37.50 |
| 52 Week Low/High: | $0.91 - $4.54 | Next Earning Date: | N/A |
| Revenue: | $31,937,000 | Revenue Growth: | 132.64% |
| Revenue Growth (this year): | -64.45% | Revenue Growth (next year): | -10.46% |
| P/E Ratio: | -1.47 | Index: | N/A |
| Free Cash Flow: | -165848000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Editas Medicine Inc. (EDIT)
EVP, CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$2.02
Shares
749
Total Value
$1,512.68
Owned After
68,028
SEC Form 4
Avg Cost/Share
$2.02
Shares
5,394
Total Value
$10,894.26
Owned After
263,693
SEC Form 4
SVP, Chief Financial Officer
Avg Cost/Share
$2.02
Shares
474
Total Value
$957.48
Owned After
15,434
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Burkly Linda | EDIT | EVP, CHIEF SCIENTIFIC OFFICER | Mar 3, 2026 | Sell | $2.02 | 749 | $1,512.68 | 68,028 | |
| O'Neill Gilmore Neil | EDIT | CEO | Mar 3, 2026 | Sell | $2.02 | 5,394 | $10,894.26 | 263,693 | |
| Parison Amy | EDIT | SVP, Chief Financial Officer | Mar 3, 2026 | Sell | $2.02 | 474 | $957.48 | 15,434 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 9, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLMar 9, 2026 · 100% conf.
1D
-5.31%
$2.19
Act: +14.29%
5D
-10.32%
$2.07
20D
-14.60%
$1.97
edit-202603090001650664FALSE00016506642026-03-092026-03-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026
Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware001-3768746-4097528 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
11 Hurley Street
Cambridge, Massachusetts02141 (Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 401-9000 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareEDITThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On March 9, 2026, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Description 99.1Press release issued by the Company on March 9, 2026*
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDITAS MEDICINE, INC.
Date: March 9, 2026 By:/s/ Amy Parison Amy Parison Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 10, 2025
Q3 2025 Earnings
8-KNov 10, 2025
edit-202511100001650664FALSE00016506642025-11-102025-11-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025
Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware001-3768746-4097528 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
11 Hurley Street
Cambridge, Massachusetts02141 (Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 401-9000 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareEDITThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On November 10, 2025, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Description 99.1Press release issued by the Company on November 10, 2025*
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDITAS MEDICINE, INC.
Date: November 10, 2025 By:/s/ Amy Parison Amy Parison Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
Q2 2025 Earnings
8-KAug 12, 2025
edit-202508120001650664FALSE00016506642025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025
Editas Medicine, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware001-3768746-4097528 (State or Other Jurisdiction of Incorporation)(Commission File Number)(IRS Employer Identification No.)
11 Hurley Street
Cambridge, Massachusetts02141 (Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (617) 401-9000 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, $0.0001 par value per shareEDITThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d)Exhibits
Exhibit No.Description 99.1Press release issued by the Company on August 12, 2025*
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
*This exhibit shall be deemed to be furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EDITAS MEDICINE, INC.
Date: August 12, 2025 By:/s/ Amy Parison Amy Parison Chief Financial Officer
Compare EDIT vs Leading Stocks
See how EDIT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "EDIT Editas Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.